Mesoblast Limited
Mesoblast Limited
Your view on MESO
Overview
What the company does, where it operates, and who runs it.
About Mesoblast Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Silviu Itescu FACP, FACRA, FRACP, MBBS
- Headquarters
- 55 Collins Street, Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Silviu Itescu FACP, FACRA, FRACP, MBBS
- Headquarters
- 55 Collins Street, Melbourne, VIC, AU
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases.
Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy.
The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.
Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Mesoblast Limited, and the rating behind it. MESO last traded at $15.50; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Mesoblast Limited. Starting points for Mesoblast Limited: EPS -$0.44, beta 0.81 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Mesoblast Limited. Mesoblast Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Mesoblast Limited. Trailing twelve-month EPS for Mesoblast Limited stands at -$0.44. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Mesoblast Limited. Mesoblast Limited has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Mesoblast Limited valued side by side against its closest peers. Mesoblast Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Mesoblast Limited, and how their positions are changing. At a $2.01B market value, institutional positions materially move Mesoblast Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Mesoblast Limited executives and directors. Shares of Mesoblast Limited have traded between $9.61 and $22.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Mesoblast Limited. Mesoblast Limited is a $2.01B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Mesoblast Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Mesoblast Limited. Coverage tracks Mesoblast Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.